Novanta (NOVT) Stock News

Novanta (Nasdaq: NOVT) will release its third quarter 2025 results on Tuesday, November 4, 2025. A conference call to discuss results is scheduled for 8:30 a.m. ET the same day.

Investors may join by phone at (888) 346-3959 or listen via a live webcast on the company’s Investors & Events page at www.novanta.com. An audio replay will be posted about three hours after the call and will remain available through Monday, December 29, 2025.

Novanta Inc. (Nasdaq: NOVT), a medical and advanced technology equipment manufacturer partner, has announced a significant expansion of its share repurchase program. The company's Board of Directors has authorized an additional $200 million for share repurchases, which adds to the existing $31 million remaining from its 2020 authorization, bringing the total capacity to $231 million.

The repurchase program has no time limit and will be funded through cash on hand and future cash flows. Shares may be purchased discretionally through various methods, including accelerated share purchase agreements, open market transactions, or private negotiations. The company maintains flexibility to suspend or discontinue the program at any time while emphasizing its commitment to both shareholder returns and strategic growth investments.

Novanta (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has announced its participation in the upcoming Baird 2025 Global Healthcare Conference. Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, will represent the company at the conference, which will take place on September 9, 2025, in New York, NY.

Novanta (Nasdaq: NOVT) reported its Q2 2025 financial results with revenue increasing 2.2% to $241.0 million. The company posted GAAP net income of $4.5 million and diluted EPS of $0.12, down from $13.8 million and $0.38 respectively in Q2 2024.

Key highlights include 10% growth in bookings and a book-to-bill ratio of 1.02. The Advanced Surgery and Robotics & Automation businesses achieved mid-teens revenue growth. The company secured significant design wins in medical devices and warehouse robotics sectors.

For full-year 2025, Novanta updated guidance to revenue of $970-985 million, Adjusted EBITDA of $225-230 million, and Adjusted EPS of $3.22-3.36. Q3 2025 revenue is expected at $244-247 million.

Novanta (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has scheduled its second quarter 2025 earnings release and conference call for Tuesday, August 5, 2025.

The conference call will begin at 10:00 a.m. ET. Investors can access the call by dialing (888) 346-3959 or via live webcast through the company's website. A replay will be available on Novanta's website until September 29, 2025.

Novanta Inc. (NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced that CFO Robert Buckley will present at the CJS Securities 25th Annual New Ideas Summer Conference. The presentation is scheduled for July 10, 2025, and will take place in White Plains, New York. Novanta, which trades on the Nasdaq, provides technology solutions to equipment manufacturers in the medical and advanced technology sectors.

Novanta (Nasdaq: NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced that its Chief Financial Officer, Robert Buckley, will be presenting at the Baird 2025 Global Consumer, Technology & Services Conference. The presentation is scheduled for June 4, 2025, and will take place in New York, NY.

Novanta (Nasdaq: NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced that its Chair & CEO Matthijs Glastra will be presenting at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for June 3, 2025, and will take place in Chicago, IL.

Novanta (NASDAQ: NOVT) reported solid Q1 2025 financial results with revenue increasing 1.1% to $233.4 million. The company achieved significant growth in GAAP net income, up 45% to $21.2 million, with diluted EPS of $0.59. Adjusted EBITDA rose 1% to $50 million, while operating cash flow was $31.7 million. For Q2 2025, Novanta expects revenue between $230-240 million and Adjusted EBITDA of $50-55 million. The company plans to implement cost containment measures targeting $20 million in annual savings to offset trade policy impacts. Despite macroeconomic uncertainties, management remains confident in meeting full-year EBITDA commitments, supported by new product launches and a recent tuck-in acquisition completed in April.